BDNF rs6265 polymorphism not linked to overactive bladder or treatment response in female patients

A recent study has found no association between the BDNF rs6265 polymorphism and the occurrence of overactive bladder (OAB) in female patients. Furthermore, the research indicated that this genetic variation does not influence the response to intradetrusor injections of botulinum neurotoxin type A, a common treatment for OAB. The findings suggest that genetic factors related to BDNF rs6265 may not play a significant role in the development or treatment outcomes of OAB in this patient group. This research contributes to a better understanding of the genetic underpinnings of OAB and its therapeutic responses.

This study's finding that BDNF rs6265 polymorphism is not associated with overactive bladder or its treatment response provides important genetic insights for understanding the condition in female patients.